Project Grant R01HL175072
Award Date 9/5/25
Completion Date 5/31/29
Dollars Obligated $644K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- This $166,752 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Trustees of Boston University to investigate the signaling mechanisms underlying lung branching morphogenesis. The project aims to combine developmental biology approaches with synthetic biology tools to elucidate the reaction-diffusion patterning that directs the assembly of the elaborate bronchial network in the lung. This work could provide...
- This $136,050 Project Grant was awarded on June 30, 2025 by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, to Tufts University School of Medicine. The grant supports research to characterize lung resident B1 cells and their impact on lung homeostasis during development. The research aims to investigate the functional role of B1 cells in developing lungs and their contribution to maintaining lung homeostasis, which...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a Project Grant of $865,694 to The Children's Hospital Corporation (Boston Children's Hospital) to investigate the role of Neuropilin-2 (NRP2) signaling in regulating lymphatic function. The research aims to define, modulate, and control NRP2 ligand-dependent signaling pathways in lymphatic endothelial cells to improve fluid drainage and alleviate...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $775,720 project grant to Yale University under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to conduct research on the role of endothelial protocadherins in vascular development and disease. The project aims to: 1) determine the effects of knocking out or inhibiting the protocadherin gamma (PCDHG) cluster in endothelial cells in mouse models of vascular inflammation, 2) elucidate the mechanism by which...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $122,625 project grant to Trustees of Boston University's Medical Campus. The grant supports research to develop induced pluripotent stem cell-derived vascular smooth muscle cells (iPSC-VSMCs) and use them for high-throughput screening of small molecules that could serve as novel therapeutics for aortic aneurysms, particularly in Marfan syndrome. The research aims to...
- This $721,826 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify molecular mechanisms regulating alveolar matrix fibroblast function and their role in supporting vascular capillary formation. The research is being conducted by Children's Hospital Medical Center in Cincinnati, Ohio to advance the understanding of alveolar septation and septal wall maturation, which is...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $705,279 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Trustees of Boston University, doing business as Boston University Medical Campus, to investigate the mechanisms by which environmental pollutants impact the cardiovascular system. The 4-year project, starting January 1, 2025, will use a multidisciplinary approach including physiological studies, cellular imaging, RNA-sequencing, and mouse models to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $594,583 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant supports research to investigate the mechanisms regulating the development, expansion, and decline of neonatal lung myofibroblasts and their role in alveologenesis. Key objectives include utilizing a novel murine model to study myofibroblast lineage, characterize...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $766,920 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant, effective May 15, 2025 through February 28, 2029, will support research by Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to investigate the mechanisms linking skeletal muscle health and vascular function in obesity. The research aims to...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...